Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LXRX Lexicon Pharmaceuticals

Pre-Mkt 04-13 04:37:43 EDT

1.72

-0.04

-2.27%

盘前1.72

+0.000.00%

04:01 EDT

High1.80	Low1.70	Vol1.37M
Open1.77	D1 Closing1.76	Amplitude5.96%
Mkt Cap728.73M	Tradable Cap718.96M	Total Shares423.68M
T/O2.36M	T/O Rate0.33%	Tradable Shares418.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LXRX","market":"US","secType":"STK","nameCN":"Lexicon Pharmaceuticals","latestPrice":1.72,"timestamp":1775851200000,"preClose":1.76,"halted":0,"volume":1368261,"hourTrading":{"tag":"盘前","latestPrice":1.72,"preClose":1.72,"latestTime":"04:01 EDT","volume":10,"amount":17.2,"timestamp":1776067263579,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.02272727272727275,"floatShares":418000000,"shares":423680611,"eps":-0.13866,"marketStatus":"Pre-Mkt","change":-0.04,"latestTime":"04-13 04:37:43 EDT","open":1.77,"high":1.7999,"low":1.695,"amount":2362240.2237984,"amplitude":0.059602,"askPrice":1.79,"askSize":116,"bidPrice":1.65,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-0.13866,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1776087000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":955080000000,"exchange":"NASDAQ","adjPreClose":1.72,"preHourTrading":{"tag":"盘前","latestPrice":1.72,"preClose":1.72,"latestTime":"04:01 EDT","volume":10,"amount":17.2,"timestamp":1776067263579,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.7187,"preClose":1.72,"latestTime":"19:20 EDT","volume":17617,"amount":30291.069,"timestamp":1775863256330,"change":-0.0013,"changeRate":-0.000756,"amplitude":0.023256},"volumeRatio":0.5680654122771601,"impliedVol":0.7927,"impliedVolPercentile":0.1325},"requestUrl":"/m/hq/s/LXRX","defaultTab":"news","newsList":[{"id":"2621064606","title":"Lexicon to present Phase 3 SCORED and SOTA-P-CARDIA sotagliflozin data at ACC 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621064606","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621064606?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:05","pubTimestamp":1774353906,"startTime":"0","endTime":"0","summary":"Lexicon announced three presentations of sotagliflozin clinical data that will be presented at the American College of Cardiology Annual Scientific Session & Expo in New Orleans, held March 28-30.One presentation will report a prespecified Phase 3 SCORED analysis stratified by baseline body mass index, showing reductions in heart failure and major adverse cardiovascular events irrespective of BMI.Two additional presentations will report analyses from the randomized, double-blind, placebo-controlled SOTA-P-CARDIA trial in symptomatic HFpEF patients without diabetes, including improved health-related quality of life and physical limitation versus placebo.Another SOTA-P-CARDIA analysis will describe findings on selective reduction of epicardial adipose tissue and hepatic fat with sotagliflozin.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL3nxbz9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NDAQ","LU2210150020.SGD","LXRX","BK4585","BK4112","LU2095319765.USD","SG9999014005.SGD","IE00BN0W2T93.GBP","SG9999014013.SGD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BN0W2W23.USD","BK4588","IE00BGHQF748.EUR","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014039.USD","IE00B64PRP62.GBP","BK4007","LU0314104364.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621970746","title":"Lexicon Pharma Price Target Maintained With a $6.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2621970746","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621970746?lang=en_us&edition=fundamental","pubTime":"2026-03-23 23:30","pubTimestamp":1774279800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 23, 2026 11:30 ET (15:30 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621702802","title":"Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Lexicon Pharmaceuticals (LXRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2621702802","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621702802?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:30","pubTimestamp":1774276207,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurogene (NGNE) and Lexicon Pharmaceuticals (LXRX) ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neurogene-ngne-and-lexicon-pharmaceuticals-lxrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neurogene-ngne-and-lexicon-pharmaceuticals-lxrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4007","XBI","HCSG","BK4137","BK4139","BK4588","NGNE","BK4581","LABU","LXRX","LU0128526141.USD","BK4585","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621708289","title":"Lexicon, Novo Nordisk announce initiation of LX9851 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2621708289","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621708289?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:46","pubTimestamp":1774266397,"startTime":"0","endTime":"0","summary":"Lexicon (LXRX) and Novo Nordisk (NVO) announced that Novo Nordisk has initiated a Phase 1 study with LX9851, an oral non-incretin development candi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexicon-novo-nordisk-announce-initiation-of-lx9851-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexicon-novo-nordisk-announce-initiation-of-lx9851-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4599","BK4007","NVOH","LU0154236417.USD","BK4532","BK4588","NVO","LU1093756325.SGD","LU1093756168.USD","BK4585","BK4139","NVOX","IE00BZ1G4Q59.USD","LXRX","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621770768","title":"Novo Nordisk initiates Phase 1 trial of Lexicon-licensed obesity candidate LX9851","url":"https://stock-news.laohu8.com/highlight/detail?id=2621770768","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621770768?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:31","pubTimestamp":1774265471,"startTime":"0","endTime":"0","summary":"Novo Nordisk initiated a Phase 1 clinical study of LX9851, an oral non-incretin drug candidate licensed from Lexicon for obesity and associated metabolic disorders.The trial is evaluating safety and tolerability, and it includes 96 participants with overweight or obesity.The study is also assessing pharmacokinetics and pharmacodynamics using single and multiple ascending doses versus placebo.Results have not been presented, and the trial is expected to be completed in Q1 2027.Lexicon earned a USD 10.0 million milestone payment tied to initial dosing and may receive up to USD 1.0 billion in total upfront and milestone payments under the agreement.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL2vYThN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2210150020.SGD","SG9999014005.SGD","IE00BGHQF748.EUR","NDAQ","BK4007","BK4585","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU2210149790.SGD","SG9999014013.SGD","SG9999014021.USD","BK4112","LXRX","LU0314104364.USD","SG9999014039.USD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","BK4588","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621770202","title":"Lexicon Pharmaceuticals Inc - Phase 1 Study of Lx9851 Expected to Complete in Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2621770202","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621770202?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:30","pubTimestamp":1774265416,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B06U:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LXRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621702737","title":"Lexicon Pharmaceuticals and Novo Nordisk Announce Initiation of Phase 1 Study With Oral Obesity Drug Candidate Lx9851","url":"https://stock-news.laohu8.com/highlight/detail?id=2621702737","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621702737?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:30","pubTimestamp":1774265416,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B06U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LXRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621702727","title":"Lexicon Pharmaceuticals Inc - Earns Second $10 Mln Milestone; Eligible for up to $1 Bln in Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2621702727","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621702727?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:30","pubTimestamp":1774265416,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B06U:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXRX","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619153251","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Rapid Micro Biosystems (RPID), Lexicon Pharmaceuticals (LXRX) and Whitehawk Therapeutics (WHWK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619153251","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619153251?lang=en_us&edition=fundamental","pubTime":"2026-03-13 00:40","pubTimestamp":1773333608,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Rapid Micro Biosystems (RPID – Research Report), Lexicon Pharmace...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-rapid-micro-biosystems-rpid-lexicon-pharmaceuticals-lxrx-and-whitehawk-therapeutics-whwk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-rapid-micro-biosystems-rpid-lexicon-pharmaceuticals-lxrx-and-whitehawk-therapeutics-whwk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["WHWK","BK4007","BK4137","BK4588","LABU","RPID","BK4585","XBI","LU0029874061.USD","BK4539","LU0128526141.USD","BK4139","LXRX","HCSG","XLV","BK4581","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618942438","title":"Lexicon announces results from post hoc analysis on data of sotagliflozin","url":"https://stock-news.laohu8.com/highlight/detail?id=2618942438","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618942438?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:17","pubTimestamp":1773231437,"startTime":"0","endTime":"0","summary":"Lexicon (LXRX) Pharmaceuticals announced that results of a post hoc analysis of clinical data evaluating the impact of kidney function on the long-...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexicon-announces-results-from-post-hoc-analysis-on-data-of-sotagliflozin-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexicon-announces-results-from-post-hoc-analysis-on-data-of-sotagliflozin-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXRX","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618442219","title":"Lexicon to present sotagliflozin kidney function analysis at ATTD conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2618442219","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618442219?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:02","pubTimestamp":1773230577,"startTime":"0","endTime":"0","summary":"Lexicon to present sotagliflozin kidney function analysis at ATTD conference               Lexicon will present results from a post hoc analysis of sotagliflozin in type 1 diabetes as a short oral pre","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL90jCBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00B3QW5Z07.USD","BK4112","LU2210150020.SGD","BK4007","SG9999014013.SGD","SG9999014005.SGD","LU2210149790.SGD","BK4139","LU0314104364.USD","IE00B64PRP62.GBP","SG9999014039.USD","LU2095319765.USD","NDAQ","BK4588","BK4585","IE00BKPKM429.USD","LXRX","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618695106","title":"Lexicon Pharma Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2618695106","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618695106?lang=en_us&edition=fundamental","pubTime":"2026-03-10 23:02","pubTimestamp":1773154920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2026 11:02 ET (15:02 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LXRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618665934","title":"Lexicon price target raised to $2.30 from $2.10 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2618665934","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618665934?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:53","pubTimestamp":1773140016,"startTime":"0","endTime":"0","summary":"Citi analyst Yigal Nochomovitz raised the firm’s price target on Lexicon (LXRX) to $2.30 from $2.10 and keeps a Buy rating on the shares. Published...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexicon-price-target-raised-to-2-30-from-2-10-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexicon-price-target-raised-to-2-30-from-2-10-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LXRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618605252","title":"Lexicon Pharmaceuticals Signals Leaner Path to Key Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2618605252","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618605252?lang=en_us&edition=fundamental","pubTime":"2026-03-10 08:14","pubTimestamp":1773101669,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals (($LXRX)) has held its Q4 earnings call. Read on for the main highlights of the call. Lexicon Pharmaceuticals’ latest earni...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-signals-leaner-path-to-key-milestones?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lexicon-pharmaceuticals-signals-leaner-path-to-key-milestones?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LXRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617636891","title":"Leerink Partners Sticks to Its Hold Rating for Lexicon Pharmaceuticals (LXRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617636891","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617636891?lang=en_us&edition=fundamental","pubTime":"2026-03-06 22:36","pubTimestamp":1772807788,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst reiterated a Hold rating on Lexicon Pharmaceuticals today and set a price target of $1.00. In addition to Leerink Partners...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leerink-partners-sticks-to-its-hold-rating-for-lexicon-pharmaceuticals-lxrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leerink-partners-sticks-to-its-hold-rating-for-lexicon-pharmaceuticals-lxrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617524999","title":"Lexicon Pharma Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2617524999","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617524999?lang=en_us&edition=fundamental","pubTime":"2026-03-06 00:49","pubTimestamp":1772729340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 05, 2026 11:49 ET (16:49 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617521761","title":"Lexicon price target raised to $6 from $4 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2617521761","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617521761?lang=en_us&edition=fundamental","pubTime":"2026-03-06 00:06","pubTimestamp":1772726790,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Lexicon (LXRX) to $6 from $4 and keeps a Buy rating on the shares following the Q4 report. The fi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexicon-price-target-raised-to-6-from-4-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexicon-price-target-raised-to-6-from-4-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXRX","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617417015","title":"Lexicon Pharmaceuticals Q4 net loss narrows on lower R&D spend","url":"https://stock-news.laohu8.com/highlight/detail?id=2617417015","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617417015?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:07","pubTimestamp":1772712435,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Q4 net loss narrows on lower R&D spendOverviewBiopharmaceutical firm's Q4 revenue decreased significantly compared to last yearNet loss for Q4 narrowed to $15.5 mln from $33.8 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nL1N3ZT0KH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4585","BK4139","LU2087621335.USD","BK4588","BK4583","LXRX","LU1839511570.USD","VTRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617416905","title":"Lexicon Pharmaceuticals Q4 EPS $(0.04) Beats $(0.07) Estimate, Sales $5.493M Beat $3.142M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2617416905","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617416905?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:00","pubTimestamp":1772712014,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Q4 EPS $(0.04) Beats $(0.07) Estimate, Sales $5.493M Beat $3.142M Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51061649/lexicon-pharmaceuticals-q4-eps-0-04-beats-0-07-estimate-sales-5-493m-beat-3-142m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617418035","title":"BRIEF-Lexicon Pharmaceuticals Q4 EPS USD -0.04","url":"https://stock-news.laohu8.com/highlight/detail?id=2617418035","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617418035?lang=en_us&edition=fundamental","pubTime":"2026-03-05 19:59","pubTimestamp":1772711985,"startTime":"0","endTime":"0","summary":"BRIEF-Lexicon Pharmaceuticals Q4 EPS USD -0.04\n\n\nMar 05 (Reuters) - Lexicon Pharmaceuticals Q4 operating income USD -14.78 million.\n\nQ4 product revenue USD 1.055 million\nQ4 basic EPS USD -0.04\nQ4 net income USD -15.53 million\nQ4 operating expenses USD 20.273 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nPLXEE7ACB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lexpharma.com","stockEarnings":[{"period":"1week","weight":0.0818},{"period":"1month","weight":0},{"period":"3month","weight":0.4701},{"period":"6month","weight":0.1544},{"period":"1year","weight":2.4726},{"period":"ytd","weight":0.4957}],"compareEarnings":[{"period":"1week","weight":0.036},{"period":"1month","weight":0.0046},{"period":"3month","weight":-0.021},{"period":"6month","weight":0.0405},{"period":"1year","weight":0.2952},{"period":"ytd","weight":-0.0036}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.040884},{"month":2,"riseRate":0.423077,"avgChangeRate":-0.046623},{"month":3,"riseRate":0.5,"avgChangeRate":-0.016324},{"month":4,"riseRate":0.461538,"avgChangeRate":0.016217},{"month":5,"riseRate":0.5,"avgChangeRate":0.029091},{"month":6,"riseRate":0.653846,"avgChangeRate":0.134775},{"month":7,"riseRate":0.5,"avgChangeRate":0.021487},{"month":8,"riseRate":0.269231,"avgChangeRate":-0.025279},{"month":9,"riseRate":0.346154,"avgChangeRate":0.011129},{"month":10,"riseRate":0.538462,"avgChangeRate":-0.006481},{"month":11,"riseRate":0.384615,"avgChangeRate":-0.041818},{"month":12,"riseRate":0.461538,"avgChangeRate":0.062158}],"exchange":"NASDAQ","name":"Lexicon Pharmaceuticals","nameEN":"Lexicon Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lexicon Pharmaceuticals(LXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lexicon Pharmaceuticals,LXRX,Lexicon Pharmaceuticals股票,Lexicon Pharmaceuticals股票老虎,Lexicon Pharmaceuticals股票老虎国际,Lexicon Pharmaceuticals行情,Lexicon Pharmaceuticals股票行情,Lexicon Pharmaceuticals股价,Lexicon Pharmaceuticals股市,Lexicon Pharmaceuticals股票价格,Lexicon Pharmaceuticals股票交易,Lexicon Pharmaceuticals股票购买,Lexicon Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lexicon Pharmaceuticals(LXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction